secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0000950170-23-060352
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology reports Q3 2023 net loss $23.0M; cuts headcount 40% to extend cash runway into early 2026
--------------------------------------------------------------------------------

- Net loss of $23.0M ($0.56 per share) for Q3 2023, vs $27.7M ($0.85 per share) in Q3 2022.
- Cash, restricted cash, and short-term investments total $134.4M as of Sept 30, 2023.
- Announces 40% headcount reduction and pausing early-stage research to extend cash runway into early 2026.
- PYX-201 Phase 1 fifth dose cohort at 3.6 mg/kg; preliminary data expected 1H 2024. PYX-106 refocused on NSCLC; data expected 2H 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000095017023060352/0000950170-23-060352-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000095017023060352/pyxs-20231107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-060352

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer